Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/vox.13038 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting molecular pathways to control immune checkpoint inhibitor toxicities.
Trends Immunol
December 2024
Heidelberg University, Medical Faculty Heidelberg, Department of Dermatology and National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg, Heidelberg, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) Core Center Heidelberg, 69120 Heidelberg, Germany. Electronic address:
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment but are frequently associated with immune-related adverse events (irAEs). This article offers a novel synthesis of findings from both preclinical and clinical studies, focusing on the molecular mechanisms driving irAEs across diverse organ systems. It examines key immune cells, such as T cell subsets and myeloid cells, which are instrumental in irAE pathogenesis, alongside an in-depth analysis of cytokine signaling [interleukin (IL)-6, IL-17, IL-4), interferon γ (IFN-γ), IL-1β, tumor necrosis factor α (TNF-α)], integrin-mediated interactions [integrin subunits αITGA)4 and ITGB7], and microbiome-related factors that contribute to irAE pathology.
View Article and Find Full Text PDFEuropean biologic training course for type 2 inflammation by EUFOREA in 2024: key facts and lessons learned.
Front Allergy
December 2024
Department of Otorhinolarynogology and Head/Neck Surgery, Amsterdam University Medical Centres, Location AMC, University of Amsterdam, Amsterdam, Netherlands.
The European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) organized the first European Biologic Training Course (EBTC) in Brussels on 1st March 2024. The aim of this hybrid EBTC including both face-to-face and web-based participation was to address the educational needs of physicians dealing with asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) on the clinically relevant aspects of diagnosing and treatment with biologics. EUFOREA is an international non-for-profit organization forming an alliance of all stakeholders dedicated to reducing the prevalence and burden of chronic respiratory diseases through the implementation of optimal patient care via educational, research, and advocacy activities.
View Article and Find Full Text PDFBackground: Although Interprofessional Education (IPE) is an important component of medical education, it has only recently come under consideration in Sub-Saharan Africa. IPE occurs when two or more professions learn from, about and with each other regarding effective collaboration and the improvement of health outcomes. Current academic programs focus more on traditional approaches to training physicians, pharmacists, respiratory therapists, physiotherapists and nurses like they were independent entities.
View Article and Find Full Text PDF[ACP and Ethics].
Gan To Kagaku Ryoho
December 2024
Graduate School of Health Sciences, Niigata University.
Since the 1970s, medical ethics has evolved from an informal approach to a more structured public discourse. The 4 principles proposed by Beauchamp and Childress in 1979 have gained international recognition and are useful for organizing ethical issues. However, this methodology has its limitations, and dialogue-based ethics are becoming increasingly important.
View Article and Find Full Text PDFConsideration of Cybersecurity Risks in the Benefit-Risk Analysis of Medical Devices: Scoping Review.
J Med Internet Res
December 2024
Else Kröner Fresenius Center for Digital Health, Dresden University of Technology, Dresden, Germany.
Background: The integration of connected medical devices (MDs) into health care brings benefits but also introduces new, often challenging-to-assess risks related to cybersecurity, which have the potential to harm patients. Current regulations in the European Union and the United States mandate the consideration of these risks in the benefit-risk analysis (BRA) required for MD approval. This important step in the approval process weighs all the defined benefits of a device with its anticipated risks to ensure that the product provides a positive argument for use.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!